BBIO — BridgeBio Pharma Inc

BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on NASDAQ. It is led by Neil Kumar Ph.D., based in 3160 Porter Drive, Palo Alto, CA, United States, 94304, with about 834 employees. BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Latest reported BBIO revenue for 2025-09-30 was $120.7M. Net income was -$184.9M. Revenue was up 9.2% from 2025-06-30 to 2025-09-30. BBIO currently screens at market cap $13.24B.

Use this BBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to BridgeBio Pharma Inc even when a live quote feed is slow.